Letter regarding article by Mehilli et al, "randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel".
Eikelboom
John W
JW
Rankin
James M
JM
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002985:Clinical Protocols / Q000592:standards; D000077144:Clopidogrel; D003925:Diabetic Angiopathies / Q000628:therapy; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D000077144:Clopidogrel; D013988:Ticlopidine; D000077284:Abciximab